<?xml version="1.0" encoding="UTF-8"?>
<front xmlns:xlink="http://www.w3.org/1999/xlink" xsi:noNamespaceSchemaLocation="D:\Docs\PMC\PMCConverter\JATS/JATS-journalpublishing1.xsd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <journal-meta>
        <journal-id journal-id-type="publisher-id">CJIDMM</journal-id>
        <journal-title-group>
            <journal-title>Canadian Journal of Infectious Diseases and Medical Microbiology</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1712-9532</issn>
        <publisher>
            <publisher-name>Pulsus Group Inc</publisher-name>
        </publisher>
    </journal-meta>
    <article-meta>
        <article-id pub-id-type="publisher-id">784635</article-id>
        <article-id pub-id-type="doi">10.1155/2009/784635</article-id>
        <article-categories>
            <subj-group>
                <subject>CANWARD 2007</subject>
            </subj-group>
        </article-categories>
        <title-group>
            <article-title>Analysis of 1560 Inpatient and Outpatient <italic>Escherichia coli</italic> Isolates from across Canada&#x2014;Results from the CANWARD 2007 Study</article-title>
        </title-group>
        <contrib-group>
             <contrib contrib-type="author" id="U16250546" corresp="yes">
                <name>
                    <surname>Lagac&#xe9;-Wiens</surname>
                    <given-names>Philippe RS</given-names>
                </name>
                <email>plagacewiens@sbgh.mb.ca</email>
                <xref ref-type="aff" rid="I1">
                    <sup>1</sup>
                </xref>
                <xref ref-type="aff" rid="I3">
                    <sup>3</sup>
                </xref>
            </contrib>
         <contrib contrib-type="author" id="U29645105">
                <name>
                    <surname>DeCorby</surname>
                    <given-names>Mel</given-names>
                </name>
                
                <xref ref-type="aff" rid="I1">
                    <sup>1</sup>
                </xref>

            </contrib>
             <contrib contrib-type="author" id="U59617549">
                <name>
                    <surname>Baudry</surname>
                    <given-names>Patricia J</given-names>
                </name>
                
                <xref ref-type="aff" rid="I1">
                    <sup>1</sup>
                </xref>

            </contrib>
             <contrib contrib-type="author" id="U52014184">
                <name>
                    <surname>Hoban</surname>
                    <given-names>Daryl J</given-names>
                </name>
                
                <xref ref-type="aff" rid="I1">
                    <sup>1</sup>
                </xref>
                 <xref ref-type="aff" rid="I2">
                    <sup>2</sup>
                </xref>
                <xref ref-type="aff" rid="I3">
                    <sup>3</sup>
                </xref>
            </contrib>
             <contrib contrib-type="author" id="U52928057">
                <name>
                    <surname>Karlowsky</surname>
                    <given-names>James A</given-names>
                </name>
                <xref ref-type="aff" rid="I1">
                    <sup>1</sup>
                </xref>
                 <xref ref-type="aff" rid="I2">
                    <sup>2</sup>
                </xref>
                <xref ref-type="aff" rid="I3">
                    <sup>3</sup>
                </xref>
            </contrib>
              <contrib contrib-type="author">
                <name>
                    <surname>The Canadian Antimicrobial Resistance Alliance (CARA)</surname>
                </name>
            
            </contrib>
              <contrib contrib-type="author" id="U17281389">
                <name>
                    <surname>Zhanel</surname>
                    <given-names>George G</given-names>
                </name>
                <email>ggzhanel@pcs.mb.ca</email>
                <xref ref-type="aff" rid="I1">
                    <sup>1</sup>
                </xref>
                <xref ref-type="aff" rid="I2">
                    <sup>2</sup>
                </xref>
              
            </contrib>
        </contrib-group>
        <aff id="I1">
            <sup>1</sup>
            <addr-line>Department of Medical Microbiology and Infectious Diseases</addr-line>
            <addr-line>Faculty of Medicine</addr-line>
            <addr-line>University of Manitoba</addr-line>
            <country>Canada</country>
            <ext-link ext-link-type="domain-name">umanitoba.ca</ext-link>
        </aff>
        <aff id="I2">
            <sup>2</sup>
            <addr-line>Clinical Microbiology</addr-line>
            <addr-line>Health Sciences Centre</addr-line>
            <country>Canada</country>
            <ext-link ext-link-type="domain-name">hsc.mb.ca</ext-link>
        </aff>
        <aff id="I3">
            <sup>3</sup>
            <addr-line>Clinical Microbiology</addr-line>
            <addr-line>St Boniface General Hospital</addr-line>
            <addr-line>Winnipeg</addr-line>
            <addr-line>Manitoba</addr-line>
            <country>Canada</country>
            <ext-link ext-link-type="domain-name">sbgh.mb.ca</ext-link>
        </aff>
        
        <pub-date pub-type="publication-year">
            <year>2009</year>
        </pub-date>
        <volume>20</volume>
        <issue>Suppl A</issue>
        <fpage>49A</fpage>
        <lpage>53A</lpage>
        <permissions>
            <copyright-year>2009</copyright-year>
            <copyright-holder>Copyright &#xa9; 2009 Hindawi Publishing Corporation.</copyright-holder>
            <license license-type="open-access">
                <license-p>This is an open access article distributed under the <ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
            </license>
        </permissions>
        <abstract>
            <p>OBJECTIVES: <italic>Escherichia coli</italic> was the most common pathogen isolated
in the Canadian Ward Surveillance Study (CANWARD 2007)
and remains one of the most common pathogens isolated in all health
care settings. An in-depth analysis of all <italic>E coli</italic> isolates was performed
to determine the distribution and demographics associated with resistance                     
to antimicrobials, presence of extended-spectrum beta-lactamases
(ESBLs) and multidrug resistance (MDR; concurrent resistance to
agents from three or more different antimicrobial classes).
METHODS: The CANWARD 2007 study characterized pathogens
isolated from inpatient (surgical and medical wards, and intensive care
units) and outpatient (emergency departments and clinics) areas of
12 Canadian hospitals between January and December 2007. <italic>E coli</italic>
susceptibility to 12 antimicrobials was determined, ESBL production
was determined, and a multivariate nominal logistic regression model
was designed to determine if sex, isolation from a sterile site, inpatient
versus outpatient status, and age were significantly associated with
susceptibility to the tested antimicrobials, MDR or ESBL production.
RESULTS: In total, 1702 <italic>E coli</italic> isolates, representing 21.6% of all
isolates collected in the CANWARD 2007 study, were investigated.
Of these, 1560 isolates fell within the primary objective of the study
and were included in the present analysis. Susceptibilities were greater
than 90% for meropenem (100%), ertapenem (100%), tigecycline
(99.9%), piperacillin-tazobactam (97.9%), cefepime (97.9%), ceftriaxone
(95.4%), nitrofurantoin (95.2%), cefoxitin (94.8%), amoxicillinclavulanate
(92.9%) and gentamicin (91.4%). Cefazolin (89.4%), the
fluoroquinolones (ciprofloxacin, 79.4%; levofloxacin, 79.9%) and
trimethoprim-sulfamethoxazole (75.7%) were less active agents. In
the multivariate model, invasive isolates were significantly associated
with lower susceptibility rates for trimethoprim-sulfamethoxazole.
Increasing age was associated with lower susceptibility to fluoroquinolones,
ceftriaxone, cefepime, gentamicin and nitrofurantoin, as well as
ESBL production. Sex was not associated with resistance to any antimicrobial
or to ESBL production. Inpatient status was associated with
higher resistance rates to amoxicillin-clavulanate, cefazolin, fluoroquinolones
and trimethoprim-sulfamethoxazole. Isolation of an ESBL
producer was only found to be independently associated with age,
being more common in older patients. MDR was not found to be associated
with any variable measured when ESBL producers were
excluded from analysis.
CONCLUSIONS: <italic>E coli</italic> antimicrobial susceptibility varies according
to patient factors. Age and inpatient status were the most important
determinants in the present analysis and should be considered when
prescribing empirical antimicrobial therapy. Fluoroquinolones and
sulfonamides should be used cautiously and in consideration of local
resistance patterns for infections caused by <italic>E coli</italic>, due to lower susceptibility
rates. Independent factors associated with antimicrobial resistance
were age, inpatient status and isolation from a sterile site. These
factors should be considered when empirically treating infections
likely caused by <italic>E coli</italic>. Local antimicrobial prescribing practices, in
particular the liberal use of fluoroquinolones, and inadequate infection
control practices may be reducing susceptibility rates.</p>
        </abstract>
        <kwd-group>
            <kwd>Gram-negative</kwd>
            <kwd>Infection</kwd>
            <kwd>Resistance</kwd>
            <kwd>Treatment</kwd>
        </kwd-group>
        <funding-group>
            <award-group>
                <funding-source>University of Manitoba</funding-source>
            </award-group>
            <award-group>
                <funding-source>Health Sciences Centre in Winnipeg</funding-source>
            </award-group>
            <award-group>
                <funding-source>National Microbiology Laboratory-Health Canada</funding-source>
            </award-group>
            <award-group>
                <funding-source>Abbott</funding-source>
            </award-group>
            <award-group>
                <funding-source>Affinium Inc</funding-source>
            </award-group>
            <award-group>
                <funding-source>Astellas</funding-source>
            </award-group>
            <award-group>
                <funding-source>http://dx.doi.org/10.13039/100004326 Bayer
</funding-source>
            </award-group>
            <award-group>
                <funding-source>Janssen Ortho Inc</funding-source>
            </award-group>
            <award-group>
                <funding-source>http://dx.doi.org/10.13039/100004334 Merck</funding-source>
            </award-group>
            <award-group>
                <funding-source>Oryx</funding-source>
            </award-group>
            <award-group>
                <funding-source>Pfizer Canada</funding-source>
            </award-group>
            <award-group>
                <funding-source>TaiGen</funding-source>
            </award-group>
            <award-group>
                <funding-source>Targanta</funding-source>
            </award-group>
            <award-group>
                <funding-source>http://dx.doi.org/10.13039/100004342 Wyeth
</funding-source>
            </award-group>
        </funding-group>
        <counts>
            <ref-count count="20"/>
            <page-count count="5"/>
        </counts>
    </article-meta>
</front>
